Subscribe

ALK Gene Rearrangement and PD-L1 Expression

Lung Cancer, Video
Videos
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.

Related Items

Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Lung Cancer
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
Lung Cancer
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Lung Cancer
Discordance Found Between Liquid and Tissue Biopsies in NGS in Patients With Non–Small Cell Lung Cancer at Disease Progression
Web Exclusives
Lung Cancer
Case Study Finds Sotorasib Effective as First-Line Treatment for NSCLC With the KRAS G12C Mutation
Web Exclusives
Lung Cancer
NGS Found More Cost-Effective Than Single-Gene Testing in Patients With NSCLC
Web Exclusives
Lung Cancer
Liquid Biopsy Found to Be Feasible Alternative to Tissue Biopsy in NSCLC
Web Exclusives
Lung Cancer
Multiple Studies Investigating KRAS G12C Inhibitors in NSCLC
Web Exclusives
Lung Cancer
Liquid Biopsy Found Effective at Capturing Genetic Alterations in NSCLC
Web Exclusives
Lung Cancer
Sotorasib Found to Have Promising Intracranial Activity in Patients with NSCLC with Brain Metastasis
Web Exclusives
Lung Cancer

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.